Table 2.
Effect of Zn supplementation on skin tumor multiplicity in Fhit −/− and wt mice
| Genotype | Treatment group | n | Total tumors/mouse | Number of tumors with size (Mean ± SD) | ||
|---|---|---|---|---|---|---|
| (Mean ± SD) | ≤0.5 mm | 1 mm | ≥2 mm | |||
| B6 wt | F | 23 | 9.1 ± 4.3 | 3.1 ± 2.6 | 4.1 ± 3.5 | 1.9 ± 1.6 |
| F + Zn | 19 | 6.9 ± 4.5 | 2.2 ± 2.3 | 2.0 ± 1.6 | 2.7 ± 2.3 | |
| M | 11 | 6.0 ± 4.3 | 1.7 ± 1.6 | 2.4 ± 2.7 | 1.9 ± 1.4 | |
| M + Zn | 10 | 10.8 ± 5.4 | 6.8 ± 4.0 | 1.5 ± 1.3 | 2.5 ± 2.1 | |
| Fhit −/− | F | 28 | 16.5 ± 8.9 | 6.8 ± 4.7 | 6.1 ± 5.1 | 3.5 ± 2.5 |
| F + Zn | 17 | 8.5 ± 6.3 | 3.2 ± 2.4 | 3.3 ± 3.7 | 2.0 ± 1.8 | |
| M | 15 | 15.9 ± 6.0 | 4.1 ± 3.6 | 7.4 ± 4.5 | 4.4 ± 3.6 | |
| M + Zn | 17 | 12 ± 4.6 | 4.3 ± 3.3 | 5.6 ± 4.0 | 2.1 ± 1.9 | |
Statistical analyses showed statistically significant differences in tumor multiplicity (number of tumors per mouse, mean ± standard deviation) in unsupplemented Fhit −/− versus unsupplemented B6 mice (16.2 tumors in Fhit −/− mice versus 7.6 tumors in wt mice, weighted averages for genotypes combining males and females), P < 0.001), as well as in tumor multiplicity in unsupplemented Fhit −/− mice versus Zn‐supplemented Fhit −/− mice (16.2 unsupplemented vs. 10.3 Zn supplemented, P = 0.001).
F, female; M, male; B6, C57BL/6J.